By Michael Susin

Redx Pharma's lung disease treatment RCX007 has received orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of idiopathic pulmonary fibrosis, the company said Monday.

The clinical-stage biotechnology company said the designation provides various development and commercial incentives, including market exclusivity, in order to address unmet demand.

The treatment is currently in a Phase 2 clinical study for IPF, with topline data expected to be released in the first quarter of 2024.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

August 21, 2023 03:02 ET (07:02 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Redx Pharma (LSE:REDX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Redx Pharma 차트를 더 보려면 여기를 클릭.
Redx Pharma (LSE:REDX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Redx Pharma 차트를 더 보려면 여기를 클릭.